Department of Gastrointestinal Surgery, The First Hospital of China Medical University, Shenyang 110001, China.
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
J Immunol Res. 2023 Mar 14;2023:5356646. doi: 10.1155/2023/5356646. eCollection 2023.
Specific biomarkers of intestinal injury associated with necrotizing enterocolitis (NEC) are needed to diagnose and monitor intestinal mucosal injury and recovery. This study aims to develop and test a modified enzyme-linked immunosorbent assay (ELISA) protocol to detect the total keratin 8 (K8) in the stool of newborns with NEC and investigate the clinical value of fecal K8 as a marker of intestinal injury specifically associated with NEC. We collected fecal samples from five newborns with NEC and five gestational age-matched premature neonates without NEC at the Lucile Packard Children's Hospital Stanford and Washington University School of Medicine, respectively. Fecal K8 levels were measured using a modified ELISA protocol and Western blot, and fecal calprotectin was measured using a commercial ELISA kit. Clinical data, including gestational age, birth weight, Bell stage for NEC, feeding strategies, total white blood cell (WBC) count, and other pertinent clinical variables, were collected and analyzed. Fecal K8 levels were significantly higher in the pre-NEC group (1-2 days before diagnosis of NEC) and NEC group than those in the non-NEC group ( = 0.013, = 0.041). Moreover, fecal K8 was relatively higher at the onset of NEC and declined after the resolution of the disease ( = 0.019). Results with similar trends to fecal K8 were also seen in fecal calprotectin ( = 0.046), but not seen in total WBC count ( = 0.182). In conclusion, a modified ELISA protocol for the total K8 protein was successfully developed for the detection of fecal K8 in the clinical setting of premature newborns with NEC. Fecal K8 is noted to be significantly increased in premature newborns with NEC and may, therefore, serve as a noninvasive and specific marker for intestinal epithelial injury associated with NEC.
需要特定的肠损伤生物标志物来诊断和监测肠黏膜损伤和恢复情况,与坏死性小肠结肠炎(NEC)相关。本研究旨在开发和测试改良的酶联免疫吸附测定(ELISA)方案,以检测患有 NEC 的新生儿粪便中的总角蛋白 8(K8),并研究粪便 K8 作为与 NEC 相关的肠损伤特异性标志物的临床价值。我们分别从斯坦福露西尔帕卡德儿童医院和华盛顿大学医学院的 5 名患有 NEC 的新生儿和 5 名胎龄匹配的早产儿中收集粪便样本。使用改良的 ELISA 方案和 Western blot 测量粪便 K8 水平,并使用商业 ELISA 试剂盒测量粪便钙卫蛋白。收集并分析了临床数据,包括胎龄、出生体重、NEC 的 Bell 分期、喂养策略、总白细胞(WBC)计数和其他相关临床变量。在预 NEC 组(在 NEC 诊断前 1-2 天)和 NEC 组中,粪便 K8 水平明显高于非 NEC 组(=0.013,=0.041)。此外,在 NEC 发病时粪便 K8 相对较高,在疾病缓解后下降(=0.019)。粪便 K8 的结果与粪便钙卫蛋白(=0.046)的趋势相似,但与总 WBC 计数(=0.182)的结果不同。总之,成功开发了一种改良的 ELISA 方案,用于检测患有 NEC 的早产儿粪便中的总 K8 蛋白。在患有 NEC 的早产儿中,粪便 K8 明显增加,因此可能成为与 NEC 相关的肠上皮损伤的非侵入性和特异性标志物。